{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 287,
  "pageCount": 415,
  "prevPage": 286,
  "nextPage": 288,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide highlights a potential safety risk identified by a KOL regarding the drug's mechanism of action.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/287",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-287",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Vykat is an ATP-sensitive potassium channel...magnesium is one of the important balancers that keeps us from not having seizures.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ae-ce56f18f4fe4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "Vykat mechanism of action in a prevalent PWS genetic subtype - potential interference with potassium/magnesium balance, which is related to blood clots and seizures",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa6140c8-b915-4ed2-8d93-a85c18924c20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.43
      },
      "kind": "quote",
      "text": "“They are metals, they are cations, they are positively charged metals. And I’ve been concerned about this in those with the type I deletion. And they account for about 1 of every 4 Prader-Willi patients — there are 7 different genetic subtypes. But one out of four of all the subtypes, 25% is actually is 6x4, which is 24%. We’ll have the type I deletion where the magnesium, iron, potassium channels will be altered because the transporter gene in this region is not making a transporter if we have problems maintaining your electrolyte balance. Electrolyte balance, what happens? Put your hands in salt water, what happens to your hands? They get all wrinkled, don’t they? Because you’re pulling water out of your hand. Imagine you got electrolyte balance in your body. You’re taking liquid out of your blood. Your blood becomes sluggish, more prone to blood clots. Or maybe putting too much liquid back into your blood, it’s getting too thin. Imagine if you have disturbances in your iron or magnesium and ATP — Vykat actually is an ATP-sensitive potassium channel. Potassium, And those are with the type I deletion will have a problem maintaining their potassium levels in their cells. And magnesium; it’s very key on magnesium. Magnesium is one of the important balancers that keeps us from not having seizures. It keeps our balance levels correct. It keeps our fluid levels balanced normally. So, this drug works on the ATP-sensitive potassium channel.” - Trial investigator and physician; one of the leading KOL’s in the PWS field",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a7a6ca6-f700-473d-a9bf-fff30dc8c09e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "quote",
      "text": "“I’ve been concerned about this in those with the type I deletion...and they account for about 1 of every 4 Prader-Willi patients...your blood becomes more sluggish, more prone to blood clots...Vykat is an ATP-sensitive potassium channel...magnesium is one of the important balancers that keeps us from not having seizures.”",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63734948-e153-4fd3-b300-cfda4a1e7e41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“They are metals, they are cations, they are positively charged metals. And I’ve been concerned about this in those with the type I deletion. And they account for about 1 of every 4 Prader-Willi patients... your blood becomes more sluggish, more prone to blood clots... Vykat is an ATP-sensitive potassium channel. Potassium, and those with the type I deletion will have a problem maintaining their potassium levels in their cells. And magnesium; it’s very key on magnesium. Magnesium is one of the important balancers that keeps us from not having seizures.” — Trial investigator and physician; one of the leading KOL’s in the PWS field",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ae-d009f97eabcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6067abf4-5291-4b97-9c46-794735986fdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #1 elaborated upon Vykat’s mechanism of action across various genetic subtypes of PWS patients and potential interference with potassium/magnesium regulation, which is related to blood clots and seizures",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "179c74e5-00e1-4bf0-9dd1-d911cb89dc3c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}